Kinase inhibitors: The next generation of therapies in the treatment of rheumatoid arthritis

International Journal of Rheumatic Diseases

Volumn 17, Issue 4, 2014, Pages 359-368

  Macfarlane, Lindsey A ^a   Todd, Derrick J ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Kinase inhibitors; Rheumatoid arthritis; Tofacitinib; Treatment

Indexed keywords

AMINOTRANSFERASE; BARICITINIB; DECERNOTINIB; FOSTAMATINIB; JANUS KINASE; JANUS KINASE INHIBITOR; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE SYK; TOFACITINIB; ANTIRHEUMATIC AGENT; PIPERIDINE DERIVATIVE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ANALGESIA; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BIOLOGICAL THERAPY; DISEASE CONTROL; DISEASE COURSE; ENZYME INHIBITION; FUNCTIONAL STATUS; HUMAN; IMMUNORECEPTOR TYROSINE BASED ACTIVATION MOTIF; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY;

ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG DESIGN; HUMANS; JANUS KINASES; MOLECULAR TARGETED THERAPY; PIPERIDINES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRIMIDINES; PYRROLES; SIGNAL TRANSDUCTION;

EID: 84901248425     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12293     Document Type: Article

References (50)

1. Firestein GS (2003) Evolving concepts of rheumatoid arthritis. Nature 423, 356-61.
2. Gabriel SE (2001) The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 27, 269-81.
3. McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365, 2205-19.
4. Weinblatt ME, Coblyn JS, Fox DA et al. (1985) Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312, 818-22.
5. Weinblatt ME (2003) Rheumatoid arthritis in 2003: where are we now with treatment? Ann Rheum Dis 62 (Suppl 2), ii94-6.
6. Lipsky PE, van der Heijde DM et al. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343, 1594-602.
7. Singh JA, Furst DE, Bharat A et al. (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 64, 625-39.
8. Blum MA, Koo D, Doshi JA (2011) Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther 33, 901-13.
9. Weinblatt ME, Kremer JM, Bankhurst AD et al. (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340, 253-9.
10. Maini R, St Clair EW, Breedveld F et al. (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354, 1932-9.
11. Weinblatt ME, Keystone EC, Furst DE et al. (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48 (1), 35-45.
12. Kremer JM, Westhovens R, Leon M et al. (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349, 1907-15.
13. Listing J, Strangfeld A, Rau R et al. (2006) Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low-results from RABBIT, the German biologics register. Arthritis Res Ther 8, R66.
14. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298, 1912-34.
15. Alten RE, Zerbini C, Jeka S et al. (2010) Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy. Ann Rheum Dis 69, 364-7.
16. Cohen SB, Cheng TT, Chindalore V et al. (2009) Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 60, 335-44.
17. Christodoulou C, Choy EH (2006) Joint inflammation and cytokine inhibition in rheumatoid arthritis. Clin Exp Med 6 (1), 13-9.
18. Damjanov N, Kauffman RS, Spencer-Green GT (2009) Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 60, 1232-41.
19. Genovese MC, Cohen SB, Wofsy D et al. (2011) A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol 38, 846-54.
20. Seavey MM, Dobrzanski P (2012) The many faces of Janus kinase. Biochem Pharmacol 83, 1136-45.
21. O'Shea JJ, Holland SM, Staudt LM (2013) JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med 368, 161-70.
22. van Vollenhoven RF (2013) Small molecular compounds in development for rheumatoid arthritis. Curr Opin Rheumatol 25, 391-7.
23. Luo C, Laaja P (2004) Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs. Drug Discov Today 9, 268-75.
24. Casanova JL, Holland SM, Notarangelo LD (2012) Inborn errors of human JAKs and STATs. Immunity 36, 515-28.
25. Kremer JM, Bloom BJ, Breedveld FC et al. (2009) The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690, 550 versus placebo. Arthritis Rheum 60, 1895-905.
26. Fleischmann R, Cutolo M, Genovese MC et al. (2012) Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690, 550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 64, 617-29.
27. Kremer JM, Cohen S, Wilkinson BE et al. (2012) A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690, 550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum 64, 970-81.
28. van Vollenhoven RF, Fleischmann R, Cohen S et al. (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 367, 508-19.
29. Fleischmann R, Kremer J, Cush J et al. (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367, 495-507.
30. Burmester GR, Blanco R, Charles-Schoeman C et al. (2013) Tofacitinib (CP-690, 550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381, 451-60.
31. van der Heijde D, Tanaka Y, Fleischmann R et al. (2013) Tofacitinib (CP-690, 550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65, 559-70.
32. Jurgen W, Silverfield JC, Lee EB et al. (2012). ABSTRACT: Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy up to 48 Months. Presented at the American College of Rheumatology Annual Scientific Meeting, Washington, DC.
33. Mariette X, Curtis JR, Lee EB (2012). ABSTRACT: Tofacitinib (CP-690, 550), an oral janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical programme. Presented at the Annual European Congress of Rheumatology; Berlin, Germany.
34. Charles-Schoeman C, Wicker P, Sechtem U (2012). ABSTRACT: Cardiovascular safety findings in rheumatoid arthritis patients treated with tofacitinib. Presented at the Annual European Congress of Rheumatology; Berlin, Germany.
35. Quintas-Cardama A, Kantarjian H, Cortes J, Verstovsek S (2011) Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 10, 127-40.
36. Fridman JS, Scherle PA, Collins R et al. (2010) Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 184, 5298-307.
37. Fleischmann R, Spencer-Green GT, Fan F (2011). Dose ranging study of VX-509, an oral selective JAK3 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA). Presented at the American College of Rheumatology Annual Meeting, Chicago, IL.
38. Vanhoutte FPM, Mazur M, Van der Aa A, Wigerinck P, van't Klooster GAE (2012) ABSTRACT: Selective JAK1 Inhibition in the Treatment of Rheumatoid Arthritis: Proof of Concept with GLPG0634. Presented at the American College of Rheumatology Annual Scientific Meeting. Washington, DC.
39. Vanhoutte FP, Van der Aa A, Meuleners L, van't Klooster GAE (2013) ABSTRACT: Safety and Efficacy of GLPG0634, a Selective JAK1 Inhibitor, in Patients with Rheumatoid Arthritis: Results of a 4-Week Phase IIA Multicenter, Dose Ranging Study. Presented at the Annual European Congress of Rheumatology; Madrid, Spain.
40. Wong BR, Grossbard EB, Payan DG, Masuda ES (2004) Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin Investig Drugs 13, 743-62.
41. Cheng AM, Rowley B, Pao W, Hayday A, Bolen JB, Pawson T (1995) Syk tyrosine kinase required for mouse viability and B-cell development. Nature 378, 303-6.
42. Mocsai A, Humphrey MB, Van Ziffle JA et al. (2004) The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci USA 101, 6158-63.
43. Cha HS, Boyle DL, Inoue T et al. (2006) A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther 317, 571-8.
44. Weinblatt ME, Kavanaugh A, Burgos-Vargas R et al. (2008) Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 58, 3309-18.
45. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB (2010) An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 363, 1303-12.
46. Genovese MC, Kavanaugh A, Weinblatt ME et al. (2011) An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 63, 337-45.
47. Weinblatt ME, Kavanaugh A, Genovese MC et al. (2013) Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial. J Rheumatol 40, 369-78.
48. Gallivan R (2013) AstraZeneca to Incur $140M Charge After Fostamatinib Disappointment. The Wall Street Journal. [Cited 4 June 2013.] Available from: http://online.wsj.com/article/BT-CO-20130604-700544.html
49. Kontzias A, Kotlyar A, Laurence A, Changelian P, O'Shea JJ (2012) Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol 12, 464-70.
50. Leonard WJ (2001) Role of Jak kinases and STATs in cytokine signal transduction. Int J Hematol 73, 271-7.